Four core genes, TREM2, GDF15, TTC39A, and ANXA2, were identified as key to influencing HCC prognosis and therapy responsiveness, especially immune treatment efficacy in NASH-associated HCC. This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatohepatitis.